BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
- 1 November 2005
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 3 (11), 2479-2486
- https://doi.org/10.1111/j.1538-7836.2005.01602.x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005
- A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJournal of Thrombosis and Haemostasis, 2005
- Prevention of Venous ThromboembolismChest, 2004
- The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyJournal of Thrombosis and Haemostasis, 2003
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee SurgeryNew England Journal of Medicine, 2001
- Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee ReplacementArchives of Internal Medicine, 2001
- Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trialsActa Radiologica, 1997
- Biologic Tolerance of Two Different Low Molecular Weight HeparinsSeminars in Thrombosis and Hemostasis, 1991
- Ventilation-perfusion studies in suspected pulmonary embolismAmerican Journal of Roentgenology, 1979
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972